Diabesity Rounds

Intensive BP control in type 2 diabetes: no significant fall in dementia or MCI

In 12 434 adults with type 2 diabetes, intensive and standard systolic targets were not significantly different for dementia or MCI; white matter lesions grew less with intensive treatment.

At a glance

  • Dementia or mild cognitive impairment occurred at 3.69 per 100 person years with a target below 120 mm Hg and 3.89 with a target below 140 mm Hg (hazard ratio 0.96, 95% CI 0.86 to 1.06; P=0.38).
  • In the MRI substudy, white matter lesion volume rose less with intensive treatment (between group difference -0.09 asinh transformed cm3, 95% CI -0.15 to -0.02).
  • The trial was open label and the MRI result is an imaging outcome. It does not show fewer cases of dementia.

The study

This is a prespecified analysis of secondary outcomes from the BPROAD randomised controlled trial, published in the BMJ. It was a multicentre, open label trial with masked outcome assessors, run at 145 clinical centres in seven regions of China. Participants were adults aged 50 years or older with type 2 diabetes, raised systolic blood pressure (SBP) and increased cardiovascular risk.

Participants were assigned to intensive treatment (SBP target below 120 mm Hg) or standard treatment (SBP target below 140 mm Hg) for up to five years. Of 12 821 randomised adults, 12 434 had no probable dementia at baseline and were included in this cognitive study: 6219 in the intensive group and 6215 in the standard group. Mean age was 63.7 years and 5567 (44.8%) were women.

The primary cognitive outcome was a composite of all cause dementia or mild cognitive impairment (MCI). A brain MRI subset (862 at baseline, 605 at the end of the study) assessed white matter lesion volume and total brain volume.

What they found

After one year, mean SBP was 121.6 mm Hg in the intensive group and 133.2 mm Hg in the standard group.

During a median follow-up of 3.8 years, dementia or MCI occurred in 747 participants in the intensive group (3.69 events per 100 person years) and 783 in the standard group (3.89 events per 100 person years). The hazard ratio was 0.96 (95% CI 0.86 to 1.06; P=0.38). The two groups were not significantly different.

In the MRI substudy (428 intensive, 434 standard), white matter lesion volume rose less in the intensive group. The between group difference was -0.09 inverse hyperbolic sine (asinh) transformed cm3 (95% CI -0.15 to -0.02; P=0.01).

The authors concluded that there was no statistically significant difference in the composite outcome, but that intensive treatment was associated with less accrual of cerebral white matter lesion volume.

How much weight to give it

The trial is randomised and large, which supports the main comparison. The confidence interval for the main cognitive result (hazard ratio 0.96, 95% CI 0.86 to 1.06) includes no difference, so no statistically significant effect was shown.

Several points limit interpretation. The trial was open label, although outcome assessors were masked. Follow-up was a median of 3.8 years, and treatment was given for up to five years, so longer effects are unknown. The MRI result comes from a subset, and fewer people had a scan at the end (605) than at baseline (862). White matter lesion volume is an imaging marker, not a clinical outcome. Its link to later dementia is not shown by this abstract.

The abstract does not report results for total brain volume, for dementia and MCI separately, or for changes in cognitive function tests. It also does not report funding or adverse events.

For your clinic

This analysis does not show that a lower SBP target reduces dementia or MCI in adults with type 2 diabetes over about four years. The MRI finding is interesting, but it should not be treated as proof of a cognitive benefit.

This abstract reports only cognitive and MRI secondary outcomes. Please read the full paper for the other outcomes, including safety, before using these results to change practice. The participants were Chinese adults aged 50 years or older with increased cardiovascular risk, so consider carefully how far the results apply to your own patients.

Source

Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial.

Wang W, Xu Y, Xu F et al.. BMJ (Clinical research ed.). 12 November 2026

Read the source · DOI 10.1136/bmj-2026-101209

Cite this report: Diabesity Rounds. Intensive BP control in type 2 diabetes: no significant fall in dementia or MCI. 2026. doi:10.5281/zenodo.24236985

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on type 2 diabetes

Go deeper